Dr Megan Crumbaker

Role: Clinical Research Fellow

Selected publications

See all publications

2025
The Lancet. Oncology10.1016/S1470-2045(25)00339-0
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Narjess Ayati, Claire Niu, Michael S Hofman, Andrew James Martin, Hayley Thomas, Ian D Davis, Martin R Stockler,
2025
European Urology Focus10.1016/j.euf.2025.03.017
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.
Mitchell G Lawrence, Shivakumar Keerthikumar, Scott L Townley, Ashlee K Clark, Georgia B Cuffe, Geraldine Laven-Law, Adrienne R Hanson, Raj K Shrestha, Todd P Knutson, Michelle G Richards, Linda Teng, Nicholas Choo, Megan Crumbaker, Anthony M Joshua, Eva Corey, Peter S Nelson, Scott M Dehm, Gail P Risbridger, Wayne D Tilley, Theresa E Hickey, Renea A Taylor, Luke A Selth
2025
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.269252
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
Louise Kostos, James P Buteau, Grace Kong, Ben Tran, Mohammad B Haskali, Michael Fahey, Megan Crumbaker, Louise Emmett, Michael S Hofman, Arun A Azad
2025
The Lancet. Oncology10.1016/S1470-2045(25)00009-9
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M Joshua, Shahneen Sandhu, Andrew Nguyen, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Craig Gedye, Natalie K Rutherford, Aravind S Ravi Kumar, David Pook, Shakher Ramdave, David P Nadebaum, Mark Voskoboynik, Andrew D Redfern, William Macdonald, Laurence Krieger, Geoff Schembri, Wei Chua, Peter Lin, Lisa Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Margaret McJannett, Hayley Thomas, Ailsa Langford, Michael S Hofman, Andrew James Martin, Ian D Davis, Martin R Stockler, ,
2024
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.267606
Comparison of Posttherapy 4- and 24-Hour [Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi, Sherrington Li, Alex Zheng, Sobia Khan, Maria Ayers, Shikha Sharma, Megan Crumbaker, Andrew Nguyen, Lyn Chan, Narjess Ayati, Louise Emmett

See all Garvan publications

Explore our research

Our impact

Our people

News and resources

About us

Support Us

Dr Megan Crumbaker

Selected publications

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.

Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.

Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.

Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.

Comparison of Posttherapy 4- and 24-Hour [Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.